The Effect of Once-Weekly Subcutaneous Semaglutide on Functional Capacity in People with Type 2 Diabetes and Peripheral Artery Disease: Primary Results From the Phase 3b, Randomized, Placebo-Controlled, Double Blind STRIDE Trial
Authors:
Marc P. Bonaca1; Andrei-Mircea Catarig2; Kim Houlind3,4*; Bernhard Ludvik5; Joakim Nordanstig6; Chethana Kalmady Ramesh7; Neda Rasouli8; Harald Sourij9; Alex Videmark2; Subodh Verma10